Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic
KEYWORDS: procedure, percutaneous, left, coronary, haemodynamic, support, patients, committee, percutaneous coronary, evidence, used, ventricle, haemodynamic support, temporary, left ventricle

support in high-risk percutaneous coronary interventions All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme. Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. 1 Recommendations 1.1 Current evidence on the safety of percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions shows there are serious, infrequent but well-recognised safety concerns. Evidence on efficacy is limited in quality. Therefore, this procedure should only be used with special arrangements for
